Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
AIDS (London, England)|April 24, 2001
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeK Van Laethem, M Witvrouw, C Pannecouque, et al.AIDS (London, England)|December 1, 1996
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddCL Ruiz, J Romeu, J Martínez-Picado, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2001
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through JE Fontaine, C Riva, M Peeters, et al.Antimicrobial Agents and Chemotherapy|February 1, 1997
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virusM Witvrouw, J Balzarini, C Pannecouque, et al.AIDS (London, England)|November 14, 1998
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countriesJ C Schmit, K Van Laethem, L Ruiz, et al.Antimicrobial Agents and Chemotherapy|March 28, 1998
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityM Witvrouw, M E Arranz, C Pannecouque, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populationsK Van Laethem, K Van Vaerenbergh, J C Schmit, et al.AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.AIDS Research and Human Retroviruses|April 18, 2002
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patientsK Van Vaerenbergh, T Harrer, J-C Schmit, et al.Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.Pageof 10